Novartis gets EC nod for Adakveo to prevent pain crises in sickle cell disease patients
Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.